Sensus Healthcare (SRTS), a maker of radiation therapy devices, dropped ~42% intraday on Friday after the company's Q3 2022 results fell short of Street forecasts while the.
The bill would have mandated insurance coverage for biomarker tests supported by medical and scientific evidence but not the prices that insurers would have to pay.